酒精性肝硬化戒酒后肝脏再代偿的发生率与意义
这项多中心研究纳入633例失代偿酒精性肝硬化患者,戒酒后中位随访36.3个月,31.1%达到Baveno VII再代偿,5年累积发生率33.8%。早期戒酒(失代偿后1个月内)和无进一步失代偿事件者再代偿可能性更高,再代偿与全因死亡率降低独立相关(aHR 0.255,p=0.001)。
要点
- 约三分之一失代偿酒精性肝硬化患者戒酒后5年内可实现再代偿。
- 失代偿后1个月内早期戒酒与再代偿可能性增加独立相关(aSHR 2.042)。
- 再代偿者持续戒酒期间无肝病相关死亡或肝细胞癌发生。
核心结论
- 戒酒可使约三分之一失代偿酒精性肝硬化患者实现肝脏再代偿,早期戒酒且无进一步失代偿事件者可能性更高。
- 再代偿与持续戒酒下显著生存获益相关,肝病相关死亡和肝细胞癌残余风险可忽略。
研究设计与样本
- 多中心研究,纳入17个中心共633例失代偿酒精性肝硬化患者,戒酒时入组至2022年12月。
- 再代偿采用Baveno VII标准定义:持续戒酒≥3个月、腹水和肝性脑病无需治疗缓解、1年内无静脉曲张出血、肝功能恢复(Child-Pugh A或MELD<10)。
主要发现
- 中位随访36.3个月(IQR 19.2-63.2),197例(31.1%)实现再代偿,累积发生率1年12.3%、2年23.4%、5年33.8%。
- 早期戒酒(失代偿后1个月内;aSHR 2.042)、较高AST(每增加10 U/L,aSHR 1.011)和GGT(每增加10 U/L,aSHR 1.004)(均p<0.001)增加再代偿可能性,存在进一步失代偿事件降低再代偿可能性(aSHR 0.650,p=0.013)。
- 随访期间123例死亡(56.1%为肝病相关),再代偿与全因死亡率降低独立相关(aHR 0.255,p=0.001)。
- 持续戒酒的再代偿患者中无肝病相关死亡或肝细胞癌发生。
关键数值与推荐
- 再代偿定义采用Baveno VII标准:持续戒酒≥3个月、腹水和肝性脑病无需治疗缓解、1年内无静脉曲张出血、Child-Pugh A或MELD<10。
- 再代偿累积发生率:1年12.3%、2年23.4%、5年33.8%。
- 早期戒酒(失代偿后1个月内)与再代偿可能性增加独立相关(aSHR 2.042,p<0.001)。
- 存在进一步失代偿事件与再代偿可能性降低独立相关(aSHR 0.650,p=0.013)。
- 再代偿与全因死亡率降低独立相关(aHR 0.255,p=0.001)。
临床怎么用
- 对失代偿酒精性肝硬化患者应尽早促成持续戒酒,尤其是失代偿后1个月内,以争取再代偿机会。
- 评估再代偿可能性时需考虑是否存在进一步失代偿事件及AST、GGT水平。
- 再代偿且持续戒酒者肝病相关死亡和肝细胞癌风险可忽略,但仍需按规范随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Alcohol abstinence enables hepatic recompensation in patients with decompensated alcohol-related cirrhosis. This study investigated the incidence, predictors, and impact of abstinence-induced recompensation. METHODS: This multicentre study included patients with decompensated alcohol-related cirrhosis recruited at the time of abstinence up to December 2022. Recompensation was defined by Baveno VII criteria: (i) sustained abstinence (≥3 months), (ii) resolution of ascites and hepatic encephalopathy off therapy, (iii) absence of variceal bleeding for 1 year, and (iv) restored liver function (Child-Pugh A or MELD <10). RESULTS: A total of 633 patients from 17 centres were included (71.7% male; median age 55 years). Alcohol-associated hepatitis superimposed on cirrhosis was present in 40.8%. Median MELD was 19 (13-24), and 47.2% had progressed to further decompensation at abstinence. Median time from index decompensation to abstinence was 0.2 (0.0-7.6) months. Over a follow-up of 36.3 (19.2-63.2) months, 197 patients (31.1%) achieved recompensation (cumulative incidence: 12.3% at 1 year, 23.4% at 2 years, 33.8% at 5 years). Early abstinence (within 1 month of decompensation; adjusted subdistribution hazard ratio [aSHR] 2.042), higher aspartate aminotransferase (aSHR per 10 U/L increase: 1.011) and gamma-glutamyltransferase (aSHR per 10 U/L increase: 1.004) (all p <0.001) increased recompensation likelihood in both supervised and machine-learning models, while the presence of further decompensation decreased it (aSHR 0.650, p = 0.013). During follow-up, 123 patients died (56.1% liver-related). Recompensation was independently associated with lower all-cause mortality (aHR 0.255, p = 0.001). No recompensated patient who remained abstinent died of liver-related causes or developed hepatocellular carcinoma. CONCLUSIONS: Alcohol abstinence enabled hepatic recompensation in approximately one-third of patients with decompensated alcohol-related cirrhosis, particularly when abstinence was achieved early and in the absence of further decompensation. Recompensation was associated with a substantial survival benefit under sustained abstinence, with a negligible residual risk of liver-related death and hepatocellular carcinoma. IMPACT AND IMPLICATIONS: Hepatic recompensation, as defined by Baveno VII, is a novel clinical concept reflecting the potential for disease regression and resolution of decompensating events in patients with cirrhosis once the underlying aetiological factor is removed or controlled. In this multicentre study, sustained alcohol abstinence led to recompensation in one-third of patients with decompensated alcohol-related cirrhosis within 5 years, particularly if abstinence was achieved early and in the absence of further decompensation. Recompensation markedly improved outcomes, with a negligible residual risk of liver-related death and hepatocellular carcinoma when abstinence was maintained. These findings support personalised treatment approaches in decompensated alcohol-related cirrhosis by enabling the identification of patients at risk of progression or with the potential for regression.
引用
- Hofer BS, Tonon M, Buttler L, et al. Incidence and implications of abstinence-induced recompensation in alcohol-related cirrhosis. J Hepatol. 2026. PMID: 41580090. doi:10.1016/j.jhep.2026.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。